Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 in Relapsed/Refractory CLL and SLL
NCT07709000Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Nov 2033
- Countries
- 2
01
Overview
A Phase 2 trial of CN201 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Merck & Co.. Started Oct 2026; status: recruiting.
02
Drugs
CN201
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07709000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709000.